Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Approved to Launch RET Inhibitor in Hong Kong for NSCLC

publication date: Jul 15, 2022

Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-positive metastatic NSCLC. Gavreto, a once daily oral selective RET inhibitor, is already approved in Mainland China and Hong Kong for other RET NSCLC and thyroid cancer indications. In 2018, CStone acquired China rights to the drug from Boston’s Blueprint Medicines in a deal worth up to $386 million. According to CStone, RET fusions account for 1-2% of all NSCLC patients, the majority of whom are non-smokers. More details....

Stock Symbols: (HK: 2616)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital